Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 30, 2011

Primary Completion Date

December 12, 2011

Study Completion Date

December 12, 2011

Conditions
Sepsis
Interventions
DRUG

SRT2379

SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.

DRUG

Placebo

For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.

Trial Locations (1)

1105 AZ

GSK Investigational Site, Amsterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Sirtris, a GSK Company

INDUSTRY

NCT01416376 - Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation | Biotech Hunter | Biotech Hunter